New data from GAP landmark trial confirm Grazax prevents asthma symptoms in children
Patients showed modified immunological responses to grass pollen, indicating inhibition of disease progression.
ALK has presented new data from the Grazax Asthma Prevention (GAP) trial with Grazax, ALK's allergy immunotherapy tablet against grass pollen allergy.
The data, presented at the 2016 Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) in Vienna, confirm that Grazax can prevent asthma symptoms, as well as offering sustained relief from grass allergy symptoms. Moreover, immunological findings were highly supportive of the disease-modifying nature of the treatment.
The GAP trial is the largest allergy immunotherapy trial ever conducted in children and investigated the effect of Grazax versus placebo on the risk of developing asthma. It involved a 3-year treatment phase and a 2-year follow-up phase and included 812 children aged 5-12 years at the start of treatment.
The detailed analysis of the GAP trial results confirmed that treatment with Grazax prevented asthma symptoms in children:
In addition, the treatment effect increased with time and was apparent both during the grass pollen season and during winter.
Moreover, the GAP trial demonstrated the efficacy of Grazax on grass allergic rhinoconjunctivitis in children, with benefits persisting for 2 years after treatment.
The trial also yielded new data, with the detailed analysis of patients' immunological response supportive of early intervention with Grazax.
Two years after treatment, Grazax-treated children were less IgE sensitised to grass pollen and had lower total IgE, both indicating a reduced allergic response. Grazax patients also had higher grass pollen-specific IgG4 levels, indicating raised immunological tolerance. Meanwhile, the wheal size from the skin prick test using grass allergen - an indicator of the extent of an allergic reaction - was significantly smaller for the Grazax group than for the placebo group.
The continued analysis of data from the GAP landmark trial follows the initial release of top-line data in January 2016. This showed that Grazax treatment significantly reduced the proportion of children experiencing asthma symptoms or using asthma medication, however there was no detectable effect in terms of time to the first diagnosis of reversible impairment of lung function and the primary endpoint of the trial was therefore not met. The safety and tolerability of Grazax were both favourable and in line with previous studies, with no new or unexpected findings.
Erkka Valovirta, paediatric allergist, Adjunct Professor at the University of Turku, Finland, and principal investigator for the GAP trial, said: "These results further enhance our understanding of allergic disease and the benefit of Grazax treatment for children whose grass allergy is not well controlled by conventional therapies. For the first time, we also see that, by treating paediatric patients early enough, we can change the trajectory of their immune system development."
He added: "The GAP trial provides further evidence that it is possible to reprogramme the allergic immune response. It also suggests there may be benefit in offering early treatment to children to minimise the risk of a lifetime of respiratory disease."
Henrik Jacobi, ALK's Executive Vice President of Research and Development, said: "We are particularly excited about these new results. They confirm the benefit of Grazax in offering sustained relief from childhood allergic rhinitis both during and after treatment. They also provide the strongest evidence yet for the early use of Grazax in children with moderate-to-severe allergies and who are at risk of developing asthma."He continued: "These insights also reaffirm ALK's position as the leading innovator in allergy treatment and further advance our understanding of the way the human immune system responds to specific allergens."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance